Evaluating the Safety and Pharmacokinetics of VRC01, VRC01LS, and VRC07-523LS, Potent Anti-HIV Neutralizing Monoclonal Antibodies, in HIV-1-Exposed Infants
PHASE1
The purpose of this study was to assess the safety and pharmacokinetics (PK...
Evaluating the Safety, Tolerability, and Effect of a Human Monoclonal Antibody (VRC01) on Markers of HIV Persistence in HIV-Infected Adults Receiving Antiretroviral Therapy (ART)
PHASE1
The purpose of this study was to evaluate the safety, tolerability, and eff...
VRC 601: A Phase I, Open-Label, Dose-Escalation Study of the Safety and Pharmacokinetics of a Human Monoclonal Antibody, VRC HIVMAB060-00-AB (VRC01), With Broad HIV-1 Neutralizing Activity, Administered Intravenously or Subcutaneously to HIV-Infected...
PHASE1
This is the first clinical trial of the VRC-HIVMAB060-00-AB (VRC01) monoclo...
Status
Completed
Location
National Institutes of Health Clinical Center, 9000 Rockville Pike